Additionally, complement-mediated therapies for STGD1, similar to those being explored for age-related macular degeneration (AMD) and geographic atrophy, are also under investigation, such as the complement C5 inhibitor (NCT03364153). This evidence concerns the gene C5 and age-related macular degeneration.